Liraglutide could reduce monthly migraine days
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other… read more.